Overview

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Status:
Completed

Trial end date:
2019-04-22

Target enrollment:

Participant gender:

Summary

This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.

Phase:

Phase 3

Details

Lead Sponsor:

Shionogi

Treatments:

Anti-Bacterial Agents